Clinical Study on Meropenem Combined with Cefoperazone Sodium and Sulbactam Sodium in the Treatment of Elderly Patients with Severe Pneumonia
Objective To explore the clinical effect of meropenem combined with cefoperazone sodium and sulbactam sodium in the treatment of elderly patients with severe pneumonia.Methods 86 elderly patients with severe pneumonia admitted to our hospital from January 2021 to February 2022 were selected and randomly divided into the reference group(n=43)and the study group(n=43).The reference group was treated with cefoperazone sodium and sulbactam sodium,and the study group was treated with meropenem combined with cefoperazone sodium and sulbactam sodium.Both groups were treated continuously for 7 days.The treatment effect,serum CRP,sICAM-1 and sTREM-1 levels,and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the research group was 95.35％,higher than 81.40％in the control group(P＜0.05).After 7 days of treatment,the serum CRP,sICAM-1 and sTREM-1 levels of the study group were lower than those of the reference group(P＜0.05).No statistical difference was found in the incidence of adverse reactions(16.28％vs.18.60％)between the two groups(P＞0.05).Conclusions Meropenem combined with cefoperazone sodium and sulbactam sodium has significant effect in the treatment of elderly patients with severe pneumonia,which can significantly reduce the serum CRP,sICAM-1 and sTREM-1 levels,and is safe and reliable.
Elderly severe pneumoniaMeropenemCefoperazone sodium and sulbactam sodiumClinical effect
国家科技期刊平台
NSTL
万方数据
